11,900 Shares in Replimune Group, Inc. (NASDAQ:REPL) Acquired by Erste Asset Management GmbH

Erste Asset Management GmbH purchased a new position in Replimune Group, Inc. (NASDAQ:REPL) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 11,900 shares of the company’s stock, valued at approximately $133,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Quest Partners LLC increased its holdings in Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after buying an additional 3,150 shares during the period. Algert Global LLC increased its holdings in Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after buying an additional 4,340 shares during the period. Creative Planning increased its holdings in Replimune Group by 28.7% in the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock worth $231,000 after buying an additional 4,699 shares during the period. Nisa Investment Advisors LLC increased its holdings in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the period. Finally, Los Angeles Capital Management LLC increased its holdings in Replimune Group by 8.1% in the 2nd quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after buying an additional 5,410 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 8.80% of the stock is currently owned by insiders.

Replimune Group Trading Up 0.2 %

Shares of REPL stock opened at $13.17 on Thursday. The stock’s fifty day moving average is $12.03 and its two-hundred day moving average is $10.14. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The firm has a market capitalization of $901.05 million, a P/E ratio of -4.32 and a beta of 1.26. Replimune Group, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $17.00.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Research analysts expect that Replimune Group, Inc. will post -2.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Jefferies Financial Group raised their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday. BMO Capital Markets raised their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd. Roth Mkm assumed coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research note on Friday, November 22nd. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $17.29.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.